MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential